AC Immune’s (ACIU) “Buy” Rating Reaffirmed at HC Wainwright

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $16.00 price objective on the stock.

AC Immune Trading Down 0.4 %

Shares of NASDAQ:ACIU opened at $2.29 on Friday. The stock has a market capitalization of $226.57 million, a PE ratio of -4.98 and a beta of 1.23. AC Immune has a 1 year low of $2.19 and a 1 year high of $4.98. The firm has a fifty day moving average price of $2.61 and a 200 day moving average price of $2.98.

Institutional Investors Weigh In On AC Immune

A number of large investors have recently bought and sold shares of ACIU. Quinn Opportunity Partners LLC bought a new stake in AC Immune during the fourth quarter valued at about $27,000. Two Sigma Advisers LP acquired a new position in shares of AC Immune during the fourth quarter valued at about $36,000. Boothbay Fund Management LLC acquired a new position in shares of AC Immune during the fourth quarter valued at about $38,000. RPO LLC acquired a new position in shares of AC Immune during the fourth quarter valued at about $51,000. Finally, Jane Street Group LLC acquired a new position in shares of AC Immune during the fourth quarter valued at about $66,000. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.